Patents
Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210)
02/2006
02/16/2006US20060035361 Novel cellulase tolerant to surfactants
02/16/2006US20060035360 Thermostable DNA polymerases and methods of making same
02/16/2006US20060035357 Novel carbonyl reductase, gene thereof and method of using the same
02/16/2006US20060035352 Production of 3-hydroxycarboxylic acid using nitrilase
02/16/2006US20060035351 Production of gamma-linolenic acid in oleaginous yeast
02/16/2006US20060035348 Method for producing an L-amino acid using a bacterium having enhanced expression of the pckA gene
02/16/2006US20060035347 Polynucleotides encoding polypeptides involved in amino acid biosynthesis in Methylophilus methylotrophus
02/16/2006US20060035344 Double-stranded rna structures and constructs, and methods for generating and using the same
02/16/2006US20060035343 The amino acid sequence corresponding to positions from 947 to 951 in a wild type carbamoylphosphate synthetase is replaced, and feedback inhibition by uridine 5'-monophosphate in the bacterium is desensitized
02/16/2006US20060035342 Engineered enzymes and their use for synthesis of thioglycosides
02/16/2006US20060035340 Fermenting an appropriate microorganism using glucose as a carbon source and operating two chromatographic separation steps wherein ion exchange chromatography is followed by hydrophobic interaction chromatography, wherein the diphtheria toxin has a purity of at least 98%.
02/16/2006US20060035337 Leukocyte adhesion inhibitor-1 polypeptide for use in the treatment of cancer, tumors, chronic infections, leukemia, T-cell mediated auto-immune diseases, parasitic infections, psoriasis, asthma, allergy, to regulate hematopoiesis, to stimulate growth factor activity, to inhibit angiogenesis
02/16/2006US20060035334 Apo-2 receptor
02/16/2006US20060035333 Transforming host expression cells with a shuttle vector containing a DNA encoding a fusion protein comprising a chitin-binding domain (CBD) and a target protein; gene expression and secretion; binding secreted fusion protein to chitin by means of CBD; chitin bead may be porous or magnetized
02/16/2006US20060035331 G-protein coupled receptors
02/16/2006US20060035330 Non aggregating fluorescent proteins and methods for using the same
02/16/2006US20060035328 Artery-and vein-specific proteins and uses therefor
02/16/2006US20060035326 Genes
02/16/2006US20060035325 Regulated apoptosis
02/16/2006US20060035324 BASB019 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
02/16/2006US20060035323 Method for producing sweetners and alcohol
02/16/2006US20060035322 T-cell epitopes in erythropoietin
02/16/2006US20060035321 Hydantoin racemase
02/16/2006US20060035319 Introducing DNA sequence encoding heterologous antigenic peptide; elicits immunogenic response; vaccine against cervical cancer
02/16/2006US20060035317 Effect of treatment with 4,5-dihydroxy-2-cyclopenten-1-one (dhcp) on gene expression and quorum-sensing in bacteria
02/16/2006US20060035316 Plasmids expressing human insulin and the preparation method for human insuling thereby
02/16/2006US20060035315 Transporters and ion channels
02/16/2006US20060035312 nucleic acid molecules encoding enzymes useful for microbial production of cyclic hydroxylated carotenoid compounds; crtZ gene, isolated from Brevundimonas vesicularis DC263
02/16/2006US20060035303 JNK3 modulators and methods of use
02/16/2006US20060035294 Use of the protein maba (fabg1) of mycobacterium tuberculosis for designing and screening antibiotics
02/16/2006US20060035293 Antibodies, polypeptides and polynucleotides, used for detection, prevention and treatment of diseases caused by gramnegative bacteria
02/16/2006US20060035289 Affinity fluorescent proteins and uses thereof
02/16/2006US20060035286 Monitor protein for measuring processing of protein
02/16/2006US20060035284 Methods for isolating molecular mimetics of unique Neisseria meningitidis serogroup B epitopes
02/16/2006US20060035276 Membrane protein library for proteome analysis and method for preparing same
02/16/2006US20060035272 Compositions and methods for use in isolation of nucleic acid molecules
02/16/2006US20060035269 Recombinational cloning using engineered recombination sites
02/16/2006US20060035268 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements
02/16/2006US20060035265 In vitro selection and optional indentification of polypeptides using solid support carriers
02/16/2006US20060035264 Processes for incorporating nucleic acid sequences into an analyte or library of analytes
02/16/2006US20060035260 Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
02/16/2006US20060035246 Chromogenic in situ hybridization methods, kits, and compositions
02/16/2006US20060035238 Composition comprising an array which further comprises chimeric compositions
02/16/2006US20060035232 making in vitro peptide expression libraries and for the isolation of nucleotide sequences encoding peptides of interest; constructing and screening DNA libraries for DNA sequences that encode biologically active molecules
02/16/2006US20060035231 micro-channels have immobilized thereon a target molecule capable of binding to an analyte present in said sample; immobilized polynucleotides
02/16/2006US20060035230 Bacterial effector proteins which inhibit programmed cell death
02/16/2006US20060035228 Method and test kit for quantitative determination of polynucleotides in a mixture
02/16/2006US20060035226 Amplification of ribonucleic acids
02/16/2006US20060035223 Method of isolating binding peptides from a combinatorial phage display library and peptides produced thereby
02/16/2006US20060035218 For in situ synthesis of oligonucleotide fragments on a solid phase microarray platform and subsequent, "on device" assembly of larger polynucleotides composed of a plurality of shorter oligonucleotide fragments
02/16/2006US20060035217 Binary probe and clamp composition.
02/16/2006US20060035216 recombinant nucleic acid; isotopic, fluorescent, chemiluminescent, enzymatic, or hapten probe; cloning vector of the nucleic acid; host cell with improved exogenous expression of the nucleic acid; biodegradation; pollution control
02/16/2006US20060035213 POSH nucleic acids, polypeptides and related methods
02/16/2006US20060034870 Increasing the immunogenicity of an antigen or a hapten by attaching it to an adjuvant having a fragment with a specific amino acid sequence of the P40 protein of Klebsiella pneumoniae to form an immunogenic complex
02/16/2006US20060034864 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
02/16/2006US20060034863 Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
02/16/2006US20060034860 Protein-protein interactions in human immunodeficiency virus
02/16/2006US20060034858 A beta or an immunogenic fragment thereof presented by a virus or bacteria as part of an immunogenic composition effective to induce an immunogenic response comprising antibodies against A beta
02/16/2006US20060034856 Epha2 antigen t epitopes
02/16/2006US20060034852 Comprising transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor moiety and an immunoglobulin moiety comprising a heavy chain constant region of an immunoglobulin; interfere with binding of a tumor necrosis factor receptor with its ligand; antitumor agents
02/16/2006US20060034843 Interaction of Smad6 with Hox proteins and uses thereof
02/16/2006US20060034835 Immunoglobulin variants and uses thereof
02/16/2006US20060034834 Intrabody-mediated control of immune reactions
02/16/2006US20060034826 contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1); inhibits signaling via PD-1
02/16/2006US20060034817 Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase
02/16/2006US20060034813 Expression of proteins in cord blood-derived endothelial cells
02/16/2006US20060034811 Melanoma vaccine and methods of making and using same
02/16/2006US20060034805 adeno-associated virus (AAV) vector for expression of a recombinant immunoglobulin; comprises self-processing cleavage site comprises a 2A sequence e.g. a Foot and Mouth Disease Virus (FMDV) sequence; cancer; treatment and prevention of infectious and autoimmune disease
02/16/2006US20060034804 Adenoviral vectors having a protein IX deletion
02/16/2006US20060034762 Method for measuring skin absorbability
02/16/2006US20060032750 Method for producing matrices of addressed ligands on a carrier
02/16/2006DE19963485B4 Verfahren zur Herstellung von Hydroxylnitril-Lyasen A process for preparing Hydroxylnitril lyases
02/16/2006DE19536506B4 Neues Creatin-Amidinohydrolase-Gen, neue rekombinante DNA und Verfahren zur Herstellung von Creatin-Amidinohydrolase New creatine amidinohydrolase gene and novel recombinant DNA method for the production of creatine amidinohydrolase
02/16/2006DE102004035074A1 P1-34-Expressionseinheiten P1-34 expression units
02/16/2006DE102004035070A1 P-180-Expressionseinheiten P-180 expression units
02/16/2006DE102004035069A1 P19-Expressionseinheiten P19 expression units
02/16/2006DE102004035067A1 P1-35-Expressionseinheiten P1-35 expression units
02/16/2006DE102004035065A1 P-ET-TS-Expressionseinheiten P-ET-TS expression units
02/16/2006DE102004034474A1 Vorrichtung und Verfahren zur effizienteren Isolierung von Nukleinsäuren Apparatus and method for efficient isolation of nucleic acids
02/16/2006CA2577306A1 Methods for constructing antibiotic resistance free vaccines
02/16/2006CA2576923A1 Vector
02/16/2006CA2576576A1 Gastrin-specific interfering rna
02/16/2006CA2576415A1 Knockout nonhuman animal
02/16/2006CA2576228A1 Compositions and methods for angiogenesis-related molecules and treatments
02/16/2006CA2576195A1 Compositions and methods for phage display of polypeptides
02/16/2006CA2576151A1 Inducible expression systems for modulating the expression of target genes in eukaryotic cells and non-human animals
02/16/2006CA2576018A1 Animal model of neurodegenerative diseases, method of obtaining same and uses thereof
02/16/2006CA2575989A1 Means and methods for producing a stabilized cell of interest
02/16/2006CA2575947A1 Modulation of bio-electrical rhythms via a novel engineering approach
02/16/2006CA2575830A1 Rage fusion proteins and methods of use
02/16/2006CA2575748A1 Nucleic acids encoding anthelmintic agents and plants made therefrom
02/16/2006CA2575582A1 17-desmethylrapamycin and analogues thereof, methods for their production and their use as immunosupressants, anticancer agents, antifungal agents, etc.
02/16/2006CA2575490A1 Method for modulating gene expression by altering the cpg content
02/16/2006CA2575446A1 Use of magnetic material to direct isolation of compounds and fractionation of multipart samples
02/16/2006CA2575293A1 Recombinant live fowlpox virus vectors and their use in pharmaceutical compositions against hepatitis c virus
02/16/2006CA2574511A1 Methods of producing mutant polynucleotides
02/16/2006CA2573775A1 Traceability of transgenic plant seeds in upstream and downstream processing
02/16/2006CA2573420A1 Lipid metabolic and signalling pathways in the epidermis
02/16/2006CA2573368A1 Improved aprotinin variants
02/16/2006CA2573339A1 Immune-compromised transgenic mice expressing human hepatocyte growth factor (hhgf)